Skip Navigation

Cardiovascular Research 2001 51(3):510-520; doi:10.1016/S0008-6363(01)00302-9
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Peter Brunner-La Rocca, H.
Right arrow Articles by Sütsch, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peter Brunner-La Rocca, H.
Right arrow Articles by Sütsch, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Therapeutic benefits of increasing natriuretic peptide levels

Hans Peter Brunner-La Rocca*, Wolfgang Kiowski, David Ramsay and Gabor Sütsch

Department of Internal Medicine, Division of Cardiology, University Hospital, Ramistrasse 100, 8091 Zurich, Switzerland

* Corresponding author. Tel.: +41-1-255-30-49; fax: +41-1-255-43-77 hanspeter.brunner{at}dim.usz.ch

Natriuretic peptides play an important role in water and salt homeostasis and in the regulation of the cardiovascular system. In recent years, exogenous administration of natriuretic peptides has primarily been used to improve our understanding of the role of natriuretic peptides. Also, it became evident that natriuretic peptides may be used therapeutically. Because of their peptide character, they cannot be administered orally and, therefore, may be used for short-term intravenous therapy only. In recent years, inhibitors of neutral endopeptidase, which degrades natriuretic peptides to inactive metabolites, have been investigated. This review focuses on the potential benefits of increasing natriuretic peptide levels, either through exogenous administration or inhibiting the degradation of endogenous natriuretic peptides.

KEYWORDS Natriuretic peptide; Heart failure; Hypertension; Vasoactive agents; Hormones; ACE inhibitors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.